Rhabdomyosarcoma is also known to show ALK aberrations, but these are different from the translocation; in a preclinical trial an ALK inhibitor seemed to be inactive against rhabdomyosarcoma [95,96]. The gene discussed is ALK; the disease is rhabdomyosarcoma.